16 December 2017
Int J Med Sci 2008; 5(4):209-217. doi:10.7150/ijms.5.209
Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer
International Medical Centre, Johns Hopkins Singapore, Singapore
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small cell lung cancers (NSCLC) and is a major target for new therapies. Specific EGFR tyrosine kinase inhibitors (TKIs) have been developed and used for the treatment of advanced NSCLC. The clinical response, however, varies dramatically among different patient cohorts. Females, East Asians, non-smokers, and patients with adenocarcinoma usually show higher response rates. Meanwhile, a number of biological factors are also associated with EGFR-TKIs responsiveness. In order to better understand the predictive value of these biomarkers and their significance in clinical application we prepared this brief review. Here we mainly focused on EGFR somatic mutations, MET amplification, K-ras mutations, EGFRvIII mutation, EGFR gene dosage and expression, HER2 gene dosage and expression, and Akt phosphorylation. We think EGFR somatic mutation probably is the most effective molecular predictor for EGFR-TKIs responsiveness and efficacy. Mutation screening test can provide the most direct and valuable guidance for clinicians to make decision on EGFR-TKIs therapy.
Keywords: non-small cell lung cancer, EGFR, somatic mutation, tyrosine kinase inhibitor, gene amplification
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhang X, Chang A. Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer. Int J Med Sci 2008; 5(4):209-217. doi:10.7150/ijms.5.209. Available from http://www.medsci.org/v05p0209.htm